- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04313218
Carbetocin Versus Misoprostol. A Retrospective Comparative Study
Carbetocin Versus Misoprostol in Reducing Blood Loss During Cesarean Section in Low Risk Patients. A Retrospective Comparative Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Cesarean section is one of the most common surgeries practiced for save delivery of the fetus, however it is not a safe route of delivery its incidence is rising especially in high and middle income countries. Although the WHO recommended cesarean section rate between 10 to 15% to decline the maternal mortality ratio and Neonatal mortality ratio, the incidence show sharp increase especially in Egypt to reach 52% of all deliveries. The major concern is that the average blood loss during cesarean delivery is 487 ml, this amount is too close to the definition of postpartum hemorrhage by WHO as loss of 500 cc of blood in the first 24 hours after delivery making control of blood loss during cesarean delivery crucial to decrease maternal morbidities. Many medications used to decrease blood loss especially placental site bleeding during cesarean section including oxytocin, ergometrine, synthetic prostaglandins and recently carbetocin.
Carbetocin is an oxytocin analogue containing eight amino acids .It binds to oxytocin receptors expressed on uterine muscles of pregnant women inducing tetanic uterine contractions for about 11 minutes after administration of 8-30ug intravenous followed by rhythmic uterine contractions that last for 60 to 120 minutes. Also it has a longer half life time than oxytocin and the recommended dose is 100ug IV.
Misoprostol is synthetic analogue to prostaglandin which is cheap heat stable uterotonic making it the alternative of choice to intravenous oxytocin in low resources countries. The recommended dose for prophylaxis against postpartum hemorrhage is 600μg while 800μg is used as a treatment.
In the lack of sufficient studies comparing the use of carbetocin to misoprostol to decrease blood loss during cesarean section we perform this study to compare the use of misoprostol to carbetocin in reducing blood loss during cesarean section.
Patients and Methods This was a retrospective comparative study conducted in Port Said General Hospital And Private practice in Port Said Egypt. Following approval of the study protocol by the ethical committee in Faculty of medicine Port Said University. The medical records of patients in the period from January 2018 to February 2019 were searched; women who underwent CS and were considered at low risk for postpartum including 1- singleton pregnancy, 2- less than previous four deliveries, 3- elective lower segment C.S, 4- C.S was done under general anesthesia 5- No medical disorders complicating pregnancy, 6- Placenta neither previa nor morbidly adherent, 7- Average amount of amniotic fluid, 8- No past history of postpartum hemorrhage and 9- No contraindications to Misopristol or Carbetocin 300 patients were eligible and were enrolled in this study. Women who received Carbetocin 100ug i.v (PABAL 100 micrograms/ml solution for injection, Ferring Pharmaceuticals Ltd) intra operative immediately after extraction of the fetus, were enrolled into group A and women who received misoprostol 600ug (cytotec 200ug tablet, Pfizer G.D. Searle LLC) rectally immediately before sterilization during caesarean section were enrolled into group B.
Maternal data (demographic and clinical), ultrasound findings, operative details, and postoperative characteristics were recorded in a database. The outcome measures of this study were the need for blood products transfusion, the amount of blood products transfusion, the operative time, operative complications uterine atony the need for surgical interventions to stop bleeding as uterine artery ligation and uterine compression sutures and the deficit in hemoglobin level.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
NY
-
Port Said, NY, Egypt, 42511
- Waleed Elsayed Elrefaie
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- parity less than 4
- unscarred uterus or previous one cesarean section
- elective C.S
- general anesthesia
Exclusion Criteria:
- medical disorders complicating pregnancy
- more than one C.S
- selective C.S
- Risk factors for Postpartum hemorrhage
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
A
recieved carbetocin 100ug iv after immediately after extraction of the fetus during cesarean section
|
iv infusion of 100ug carbetocin after extraction of the fetus during cesarean section
Other Names:
|
B
women who received misoprostol 600ug rectally immediately before sterilization during cesarean section
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
blood loss
Time Frame: during operation
|
reduction of blood loss during cesarean section operation
|
during operation
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OBSGYN 1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cesarean Section Complications
-
Assiut UniversityNot yet recruitingCesarean Section Complications | Cesarean Section Niche
-
Recep Tayyip Erdogan University Training and Research...CompletedCesarean Section Complications | Cesarean Section; DehiscenceTurkey
-
Ataturk UniversityUnknownCesarean Section Complications | Cesarean Section; Complications, Wound, Dehiscence | Cesarean Section, Repeated | Cesarean, Uterine Scar Thickness | Cesarean, Residual Myometrial ThicknessTurkey
-
Kanuni Sultan Suleyman Training and Research HospitalCompletedCesarean Section Complications | Cesarean Section; DehiscenceTurkey
-
University of CalgaryNot yet recruitingCesarean Section ComplicationsCanada
-
Peking University People's HospitalNot yet recruiting
-
Aswan University HospitalCompletedCesarean Section ComplicationsEgypt
-
Gaziosmanpasa Research and Education HospitalUnknownCesarean Section ComplicationsTurkey
-
Ain Shams UniversityUnknownCesarean Section ComplicationsEgypt
-
Mohamed Abdelrady MohamedCompletedCesarean Section ComplicationsEgypt
Clinical Trials on Carbetocin
-
Ciusss de L'Est de l'Île de MontréalCompletedCesarean Section Complications | Hemodynamic InstabilityCanada
-
University Hospital, Basel, SwitzerlandObstetric Anaesthetists' Association United KingdomCompletedAnesthesia; Reaction | Complications; Cesarean SectionSwitzerland
-
Levo Therapeutics, Inc.CompletedPrader-Willi SyndromeUnited States, Canada, Australia
-
University of British ColumbiaEdwards LifesciencesCompletedPregnancy | Effect of Carbetocin on Cardiovascular SystemCanada
-
Bezmialem Vakif UniversityCompleted
-
Cairo UniversityCompletedAbdominal MyomectomyEgypt
-
Cairo UniversityRecruitingPostpartum HemorrhageEgypt
-
Sohag UniversityAl-Azhar UniversityUnknownPostpartum HemorrhageEgypt
-
National University Hospital, SingaporeNational Healthcare Group, SingaporeCompleted
-
Cairo UniversityCompletedPost Partum Hemorrhage | Obesity, MaternalEgypt